MYASTHENIA GRAVIS (MG)
Clinical trials for MYASTHENIA GRAVIS (MG) explained in plain language.
Never miss a new study
Get alerted when new MYASTHENIA GRAVIS (MG) trials appear
Sign up with your email to follow new studies for MYASTHENIA GRAVIS (MG), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a single injection calm lupus, MG, and scleroderma?
Disease control Recruiting nowThis early study tests an experimental treatment called EVM18001 in 12 people with active, hard-to-treat lupus, myasthenia gravis, or scleroderma. The treatment uses a type of cell therapy (CAR-T) to target and possibly reset the immune system. The main goals are to check safety …
Matched conditions: MYASTHENIA GRAVIS (MG)
Phase: NA • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated May 17, 2026 00:51 UTC
-
CAR t cells take on autoimmune diseases in first human trial
Disease control Recruiting nowThis early-phase study tests a new treatment called HBI0101 CAR T for people with severe autoimmune diseases like lupus, multiple sclerosis, and rheumatoid arthritis that haven't improved with standard care. The treatment uses a patient's own immune cells, modified to target and …
Matched conditions: MYASTHENIA GRAVIS (MG)
Phase: PHASE1 • Sponsor: Polina Stepensky • Aim: Disease control
Last updated May 17, 2026 00:50 UTC
-
Experimental cell therapy targets tough autoimmune conditions
Disease control Recruiting nowThis early-stage study tests a new cell therapy called QH103 in 6 people with severe autoimmune diseases like multiple sclerosis and myasthenia gravis that haven't responded to standard treatments. The therapy uses specially engineered immune cells to target and calm the overacti…
Matched conditions: MYASTHENIA GRAVIS (MG)
Phase: PHASE1 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated May 11, 2026 20:51 UTC
-
Engineered immune cells take on multiple sclerosis and other autoimmune disorders
Disease control Recruiting nowThis early-phase study tests a new treatment called RD06-05, which uses specially engineered immune cells (CAR-T cells) to target and calm the overactive immune system in people with neurological autoimmune diseases like multiple sclerosis, myasthenia gravis, chronic inflammatory…
Matched conditions: MYASTHENIA GRAVIS (MG)
Phase: EARLY_PHASE1 • Sponsor: Daishi Tian • Aim: Disease control
Last updated May 05, 2026 11:57 UTC